Simplify Logo

Full-Time

Associate Director

Pharmacology

Confirmed live in the last 24 hours

4D Molecular Therapeutics

4D Molecular Therapeutics

51-200 employees

Develops gene therapies for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$162k - $210kAnnually

Senior

Oakland, CA, USA

Hybrid or on-site work schedule can be accommodated.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Adobe Photoshop
R
MATLAB
Data Analysis
Requirements
  • PhD. in Pharmacology, Pharmaceutics, Pharmacokinetics and Metabolism, Pharmacometrics, Biomedical Engineering, Computational Biology, or related field
  • 10+ years of industry with relevant pharmaceutical development experience
  • Independent scientist with a strong background in ADME and/or clinical pharmacology
  • Strong Scientific acumen as demonstrated by first or last-author publications in peer-reviewed scientific journals and ability to work in a matrixed environment
  • Previous experience in cross-functional teams and in a scientific or clinical setting supporting drug development.
  • Experience with AAV therapeutics development is strongly preferred
  • Successfully demonstrated ability to conduct research with solid attention to detail and rigorously analyze and interpret PK/PD, biomarker, and immunogenicity data
  • Sound knowledge of DMPK and PK/PD analysis principles; experience in PK/PD modeling and simulation is highly desirable
  • Proficiency in standard pharmacometrics software, such as Phoenix WinNonlin/NLME, NONMEM, Watson, MONOLIX, WinBUGS, STAN, or Matlab, R or S+.
  • Working knowledge of FDA, EMA, and ICH guidances relevant to AAV therapeutics development, immunogenicity assessments, and bioanalytical methods
  • Ability to multi-task and support more than one project simultaneously
  • Highly organized and motivated; self-starter with strong analytical and problem-solving skills
  • Strong work ethic, flexibility, and cooperative can-do attitude
  • Ability to work in a team-based environment; supportive of multiple viewpoints and approaches
  • Strong communication skills (both written and oral) with demonstrated ability to present ideas, information, and data effectively via one-on-one discussions, team meetings, and external partnership interactions
  • Understanding and knowledge of key scientific software programs (including Microsoft Office, JMP or Prism, and Adobe Photoshop).
Responsibilities
  • Leading design, execution, and analysis of PK/PD, biodistribution, metabolism, germline transmission, and shedding studies in AAV therapeutics programs
  • Applying quantitative skills to support model-based drug development and address complex issues via modeling and simulation, e.g. candidate selection, dose optimization
  • Analyzing data using next-gen analytical techniques, and presenting data to line management, cross-functional teams, study teams, and regulatory agencies
  • Leveraging a strong understanding of bioanalytical assays to analyze and interpret PK/PD data to drive key decisions in AAV product development, e.g., FIH dose selection
  • Assessing potential impact from immunogenicity of therapeutic candidates on PK, PD biomarkers, and clinical efficacy or safety endpoints
  • Utilizing appropriate scientific approaches to understand characteristics of AAV vector-mediated gene expression and transgenic protein function
  • Support the preparation of content for regulatory interactions and submissions (e.g. pre-IND Briefing Books, IND filings, Orphan Drug Designation, EMA submissions)
  • Representing Biomarkers & Immunology function on cross-functional teams
  • Collaborating with bioanalytical teams to forecast analytical requirements for projects and assess suitable method performance
  • Effectively mentoring junior level staff and acting as a resource for scientific expertise
  • May lead dedicated subteams responsible for analysis of PK, PD biomarkers, immunogenicity, and molecular endpoints in investigational AAV therapeutics programs
  • Maintaining current awareness of scientific literature and regulatory guidance
  • Writing and reviewing technical documents, study protocols and reports, manuscripts and presenting results at scientific meetings
  • Maintaining compliance with company Environmental Health and Safety policies, procedures, and practices
  • Contributing to building a culture that embraces continuous learning, improvement, and innovation and encourages team members to expand their skill base and deepen their gene therapy expertise.
4D Molecular Therapeutics

4D Molecular Therapeutics

View

4D Molecular Therapeutics develops gene therapies aimed at treating serious genetic diseases by delivering specific genetic material to patients' cells. The company utilizes a unique technology called Therapeutic Vector Evolution to create adeno-associated virus (AAV) vectors, which act as delivery vehicles for therapeutic genes targeting affected cells. Unlike many competitors, 4DMT focuses on precision medicine for genetic disorders, including cystic fibrosis, and emphasizes rigorous research and clinical trials to ensure the safety and effectiveness of its therapies. The company's goal is to commercialize these gene therapies through direct sales or partnerships with larger pharmaceutical firms, while also securing funding to support its development efforts.

Company Stage

IPO

Total Funding

$595M

Headquarters

Emeryville, California

Founded

2013

Growth & Insights
Headcount

6 month growth

19%

1 year growth

36%

2 year growth

59%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful clinical trials, such as the positive interim data from the Phase 1/2 AEROW trial, bolster confidence in 4DMT's therapeutic pipeline.
  • The recent $75 million Series C financing provides substantial capital to advance R&D and clinical programs.
  • The appointment of experienced executives, like Uneek Mehra as Chief Financial and Business Officer, strengthens the company's leadership team.

What critics are saying

  • The biopharmaceutical market is highly competitive, with numerous companies vying to develop similar gene therapies.
  • Regulatory hurdles and clinical trial setbacks, such as the initial clinical hold on 4D-310, can delay product development and commercialization.

What makes 4D Molecular Therapeutics unique

  • 4DMT leverages its proprietary 'Therapeutic Vector Evolution' technology to create advanced AAV vectors, setting it apart from competitors in the gene therapy space.
  • The company's focus on aerosolized genetic medicines, such as 4D-710 for cystic fibrosis, highlights its innovative approach to gene delivery.
  • Strategic partnerships, like the $962M deal with Astellas Pharma, underscore 4DMT's ability to attract significant investment and collaboration opportunities.

Help us improve and share your feedback! Did you find this helpful?